{"title":"多柔比星相关心脏毒性：心血管系统损伤的基本途径回顾。","authors":"Ashot Avagimyan , Nana Pogosova , Lev Kakturskiy , Mohammad Sheibani , Abhiram Challa , Eugenia Kogan , Federica Fogacci , Liudmila Mikhaleva , Rositsa Vandysheva , Marianna Yakubovskaya , Andrea Faggiano , Stefano Carugo , Olga Urazova , Behnaz Jahanbin , Ekaterina Lesovaya , Srujana Polana , Kirill Kirsanov , Yasar Sattar , Artem Trofimenko , Tatiana Demura , Nizal Sarrafzadegan","doi":"10.1016/j.carpath.2024.107683","DOIUrl":null,"url":null,"abstract":"<div><p>Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy.</p><p>Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies.</p><p>This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy.</p></div>","PeriodicalId":9451,"journal":{"name":"Cardiovascular Pathology","volume":"73 ","pages":"Article 107683"},"PeriodicalIF":2.3000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury\",\"authors\":\"Ashot Avagimyan , Nana Pogosova , Lev Kakturskiy , Mohammad Sheibani , Abhiram Challa , Eugenia Kogan , Federica Fogacci , Liudmila Mikhaleva , Rositsa Vandysheva , Marianna Yakubovskaya , Andrea Faggiano , Stefano Carugo , Olga Urazova , Behnaz Jahanbin , Ekaterina Lesovaya , Srujana Polana , Kirill Kirsanov , Yasar Sattar , Artem Trofimenko , Tatiana Demura , Nizal Sarrafzadegan\",\"doi\":\"10.1016/j.carpath.2024.107683\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy.</p><p>Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies.</p><p>This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy.</p></div>\",\"PeriodicalId\":9451,\"journal\":{\"name\":\"Cardiovascular Pathology\",\"volume\":\"73 \",\"pages\":\"Article 107683\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1054880724000796\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1054880724000796","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury
Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy.
Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies.
This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy.
期刊介绍：
Cardiovascular Pathology is a bimonthly journal that presents articles on topics covering the entire spectrum of cardiovascular disease. The Journal''s primary objective is to publish papers on disease-oriented morphology and pathogenesis from clinicians and scientists in the cardiovascular field. Subjects covered include cardiovascular biology, prosthetic devices, molecular biology and experimental models of cardiovascular disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
